Clinical Trial

Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease

Study acronym: HaploSCD
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 8, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is being done to determine the safety and outcome (long-term control) of a high-dose chemotherapy regimen followed by an infusion of CD34 selected (immune cells) stem cells from a partially matched adult family member donor, called haploidentical stem cell transplantation, in high-risk sickle cell disease patients. Funding Source - FDA OOPD
Protocol Amendment History 27 amendments
This ClinicalTrials.gov record has been amended 27 times since 2011-10-26; most recent amendment 2025-08-07.
Status change: Recruiting → Active, Not Recruiting 2020-09-01
Status change: Not Yet Recruiting → Recruiting 2012-04-16
Trial Details
NCT Number NCT01461837
Lead Sponsor New York Medical College
Collaborators: UCSF Benioff Children's Hospital Oakland, Medical College of Wisconsin, Washington University School of Medicine, Tufts Medical Center, University of California, San Francisco, University of California, Los Angeles, Miltenyi Biomedicine GmbH, Ann & Robert H Lurie Children's Hospital of Chicago
Conditions Sickle Cell Disease
Enrollment 21 participants
Start Date 2012-01
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-08